{"content":"<li class=\"n-box-item date-title\" data-end=\"1577163599\" data-start=\"1577077200\" data-txt=\"Monday, December 23, 2019\">Today - Monday, December 23, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3528295\" data-ts=\"1577141953\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMC\" target=\"_blank\">AMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528295-theater-stocks-fade-on-disappointing-disney-film-debut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Theater stocks fade on disappointing Disney film debut</a></h4><ul><li>Movie theater chains AMC Entertainment (<a href='https://seekingalpha.com/symbol/AMC' title='AMC Entertainment Holdings, Inc.'>AMC</a> <font color=\"red\">-5.3%</font>) and Cinemark (<a href='https://seekingalpha.com/symbol/CNK' title='Cinemark Holdings, Inc.'>CNK</a> <font color=\"red\">-3.1%</font>) <a href=\"https://finance.yahoo.com/news/theater-stocks-fall-box-office-175130668.html\" target=\"_blank\">fell sharply</a> in today's trade following a <a href=\"https://seekingalpha.com/news/3528057-skywalker-tops-box-office-smallest-haul-of-new-trilogy\" target=\"_blank\">disappointing opening</a>  for Disney's (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>) latest <em>Star Wars</em> installment.</li><li>Sales data showed the movie generated $176M in its first three days, making it the third largest December debut ever but tracking well  below the opening weekend take of its two predecessors in the trilogy and slightly below the $183M forecast by Box Office Pro.</li><li>North American movie ticket sales probably fell by 3.6% in 2019 to $11.5B, according to Comscore estimates, as a string of Disney hits including <em>Avengers: Endgame</em>, <em>The Lion King</em> and the newly released <em>Star Wars: The Rise of Skywalker</em> apparently will not be enough to lift the overall industry.</li><li>Also, Imax (NYSE:<a href='https://seekingalpha.com/symbol/IMAX' title='IMAX Corporation'>IMAX</a>), the operator of big-screen format theaters, closed <font color=\"red\">-3.7%</font>, while Cineworld (<a href='https://seekingalpha.com/symbol/CNNWF' title='Cineworld Group plc'>OTCPK:CNNWF</a>), which owns the Regal chain, slipped 0.6% in London trade.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528295\" data-linked=\"Theater stocks fade on disappointing Disney film debut\" data-tweet=\"$AMC $CNK $IMAX - Theater stocks fade on disappointing Disney film debut https://seekingalpha.com/news/3528295-theater-stocks-fade-on-disappointing-disney-film-debut?source=tweet\" data-url=\"https://seekingalpha.com/news/3528295-theater-stocks-fade-on-disappointing-disney-film-debut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>67&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528294\" data-ts=\"1577140582\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528294-cvm-nlnk-pd-and-clsd-among-after-hours-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CVM, NLNK, PD and CLSD among after hours movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color=\"green\">+14.3%</font>. <a href='https://seekingalpha.com/symbol/OTIC' title='Otonomy, Inc.'>OTIC</a> <font color=\"green\">+5.2%</font>. <a href='https://seekingalpha.com/symbol/PD' title='PagerDuty, Inc.'>PD</a> <font color=\"green\">+4.1%</font>. <a href='https://seekingalpha.com/symbol/KNSL' title='Kinsale Capital Group, Inc.'>KNSL</a> <font color=\"green\">+3.0%</font>. <a href='https://seekingalpha.com/symbol/CLSD' title='Clearside Biomedical, Inc.'>CLSD</a> <font color=\"green\">+2.9%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/CVM' title='CEL-SCI Corporation'>CVM</a> <font color=\"red\">-10.8%</font>.<strong> </strong><a href='https://seekingalpha.com/symbol/CURR' title='CURE Pharmaceutical Holding Corp.'>OTCQB:CURR</a> <font color=\"red\">-6.6%</font>. <a href='https://seekingalpha.com/symbol/VCRA' title='Vocera Communications, Inc.'>VCRA</a> <font color=\"red\">-3.8%</font>. <a href='https://seekingalpha.com/symbol/UPLD' title='Upland Software, Inc.'>UPLD</a> <font color=\"red\">-1.6%. </font><a href='https://seekingalpha.com/symbol/TENB' title='Tenable Holdings, Inc.'>TENB</a> <font color=\"red\">-1.4%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528294\" data-linked=\"CVM, NLNK, PD and CLSD among after hours movers\" data-tweet=\"$NLNK $OTIC $PD - CVM, NLNK, PD and CLSD among after hours movers https://seekingalpha.com/news/3528294-cvm-nlnk-pd-and-clsd-among-after-hours-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3528294-cvm-nlnk-pd-and-clsd-among-after-hours-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528291\" data-ts=\"1577139742\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OTIC\" target=\"_blank\">OTIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528291-otonomyplus-5-on-new-bullish-start\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Otonomy +5% on new bullish start</a></h4><ul><li>Oppenheimer starts Otonomy (NASDAQ:<a href='https://seekingalpha.com/symbol/OTIC' title='Otonomy, Inc.'>OTIC</a>) with an Outperform rating and $8 price target, a 217% upside. The company has a Very Bullish average <a href=\"https://seekingalpha.com/symbol/OTIC/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li><li>Last month, Otonomy <a href=\"https://seekingalpha.com/news/3514895-otonomy-eps-beats-0_12-misses-on-revenue\" target=\"_blank\">reported</a> mixed Q3 results that beat on EPS but missed on revenue.</li><li>OTIC shares are <font color=\"green\">up 5.2%</font> after hours to $2.65.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528291\" data-linked=\"Otonomy +5% on new bullish start\" data-tweet=\"$OTIC - Otonomy +5% on new bullish start https://seekingalpha.com/news/3528291-otonomyplus-5-on-new-bullish-start?source=tweet\" data-url=\"https://seekingalpha.com/news/3528291-otonomyplus-5-on-new-bullish-start\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528276\" data-ts=\"1577136283\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLNK\" target=\"_blank\">NLNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528276-newlinkplus-16-on-nlg207-license-agreement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NewLink +16% on NLG207 license agreement</a></h4><ul><li>NewLink Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a>) <a href=\"https://seekingalpha.com/pr/17735859-newlink-genetics-announces-exclusive-worldwide-license-agreement-ellipses-pharma-for\" target=\"_blank\">enters</a> into a license agreement with Ellipses Pharma.</li><li>Ellipses bought NLNK's inventory of NLG207 related materials and gained the rights to develop and commercialize CRLX-301.</li><li>NewLink has the potential to receive future royalties or economic share related to NLG207.</li><li>NLNK shares are <font color=\"green\">up 16.4%</font> after hours to $2.27.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528276\" data-linked=\"NewLink +16% on NLG207 license agreement\" data-tweet=\"$NLNK - NewLink +16% on NLG207 license agreement https://seekingalpha.com/news/3528276-newlinkplus-16-on-nlg207-license-agreement?source=tweet\" data-url=\"https://seekingalpha.com/news/3528276-newlinkplus-16-on-nlg207-license-agreement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528270\" data-ts=\"1577135079\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EVH\" target=\"_blank\">EVH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528270-kentucky-governor-to-rebid-states-medicaid-managed-care-contracts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kentucky governor to rebid state&#39;s Medicaid managed care contracts</a></h4><ul><li>Evolent Health (<a href='https://seekingalpha.com/symbol/EVH' title='Evolent Health, Inc.'>EVH</a> <font color='green'>+6.7%</font>) shares pop following news that Kentucky's Gov. Beshear will <a href=\"https://wfpl.org/beshear-cancels-bevins-medicaid-contracts-will-redo-process-next-year/\" target=\"_blank\">cancel and rebid</a> the state's Medicaid managed care contracts that former Gov. Bevin approved shortly before he left office.</li><li>The news means Passport Health - which EVH plans to buy - and Anthem Kentucky (<a href='https://seekingalpha.com/symbol/ANTM' title='Anthem, Inc.'>ANTM</a> <font color='green'>+0.1%</font>), the Medicaid providers whose  contracts were not renewed <a href=\"https://seekingalpha.com/news/3522421-evolent-health-plunges-after-kentucky-medicaid-contract-news\" target=\"_blank\">last month</a> by outgoing Gov. Bevin last month, have  a new opportunity to apply during the  rebidding process.</li><li>Beshear criticizes Bevin's attitude toward Passport, whose enrollees are mostly in Louisville and which suffered when the state changed reimbursement rates last year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528270\" data-linked=\"Kentucky governor to rebid state&#39;s Medicaid managed care contracts\" data-tweet=\"$EVH $ANTM - Kentucky governor to rebid state&#39;s Medicaid managed care contracts https://seekingalpha.com/news/3528270-kentucky-governor-to-rebid-states-medicaid-managed-care-contracts?source=tweet\" data-url=\"https://seekingalpha.com/news/3528270-kentucky-governor-to-rebid-states-medicaid-managed-care-contracts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528267\" data-ts=\"1577134464\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528267-amdplus-3-on-street-high-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMD +3% on Street-high target</a></h4><ul><li>RBC raises its AMD (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) price target from $50 to $53 and maintains an Outperform rating. The company has a Bullish average <a href=\"https://seekingalpha.com/symbol/AMD/ratings/author-ratings#filter=all\" target=\"_blank\">SA Author's rating</a>.</li><li>Analyst Mitch Steves cites improving data center demand and the firm's optimism on margin ramps through 2020.</li><li>The firm thinks estimate raises for semi stocks will start in Q1 and that some data center build outs were pushed into that quarter.</li><li>AMD shares are <font color=\"green\">up 2.9%</font> to $45.42.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528267\" data-linked=\"AMD +3% on Street-high target\" data-tweet=\"$AMD - AMD +3% on Street-high target https://seekingalpha.com/news/3528267-amdplus-3-on-street-high-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3528267-amdplus-3-on-street-high-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528261\" data-ts=\"1577132472\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BA\" target=\"_blank\">BA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528261-boeings-muilenburg-to-go-after-botching-max-what-comes-next\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boeing&#39;s Muilenburg had to go after botching MAX but what comes next?</a></h4><ul><li>Boeing (<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color='green'>+3%</font>) shares, which have slipped more than 20% over the past nine months, rise 3% today to lead all 30 Dow stocks after the company <a href=\"https://seekingalpha.com/news/3528115-ceo-muilenberg-gets-boot-boeing\" target=\"_blank\">canned CEO Dennis Muilenburg</a> in  the wake of the 737 MAX crisis.</li><li>\"<a href=\"https://www.marketwatch.com/story/boeings-muilenburg-had-to-go-after-botching-the-handling-of-737-max-disasters-analyst-says-2019-12-23\" target=\"_blank\">Boeing's MAX response has been a failure</a> - and as a result we think it is wholly appropriate for the board to replace Muilenburg,\" says Vertical Research's Robert Stallard.</li><li>Muilenburg \"is responsible for what Boeing has said and done in reaction to the two tragic fatal accidents... [which] has arguably come from a corporate identity that under his leadership has been less than humble.\"</li><li>Aerospace analyst Richard Aboulafia of Teal Group says new CEO David Calhoun, who previously served as head of Blackstone's P-E portfolio operation, will provide short-term stability but <a href=\"https://www.reuters.com/article/us-boeing-737-max-ceo/boeing-ditches-ceo-muilenburg-in-bid-to-contain-737-max-crisis-idUSKBN1YR1FL\" target=\"_blank\">not the long-term \"emphasis on engineering\"</a> Boeing needs.</li><li>\"Calhoun is respected in the industry,\" Aboulafia says, \"but long-term, does he bring the right tool kit? Private equity leans companies out. That's not Boeing\u2019s problem right now.\"</li><li>CNBC's Jim Cramer says the CEO <a href=\"https://www.cnbc.com/2019/12/23/boeing-ceo-had-to-be-fired-in-order-for-737-max-to-get-faa-certified-jim-cramer-says.html\" target=\"_blank\">had to be fired for the MAX to receive regulatory approval</a>, as \"it was impossible to get clearance with all these different entities as  long as he was there, because he presided over what happened.\"</li><li>Muilenburg also was hurt by scrutiny earlier this fall during congressional testimony that Cramer calls a \"disaster.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3528261\" data-linked=\"Boeing&#39;s Muilenburg had to go after botching MAX but what comes next?\" data-tweet=\"$BA - Boeing&#39;s Muilenburg had to go after botching MAX but what comes next? https://seekingalpha.com/news/3528261-boeings-muilenburg-to-go-after-botching-max-what-comes-next?source=tweet\" data-url=\"https://seekingalpha.com/news/3528261-boeings-muilenburg-to-go-after-botching-max-what-comes-next\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>49&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528259\" data-ts=\"1577131800\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYGN\" target=\"_blank\">MYGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528259-myriadminus-8_6-after-wsj-genetic-test-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Myriad -8.6% after WSJ genetic test report</a></h4><ul><li>Myriad Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/MYGN' title='Myriad Genetics, Inc.'>MYGN</a>) <font color=\"red\">drops 8.6%</font> after last Friday's <a href=\"https://www.wsj.com/articles/seven-women-in-a-family-chose-surgery-after-a-genetic-test-then-the-results-changed-11576860210\" target=\"_blank\">WSJ report</a> about the company reclassifying a BRCA gene variant from \"pathogenic\" to \"unknown significance.\"</li><li>Myriad says the change was made after more people with the variant were tested and added to MYGN's database.</li><li>The reclassifying is very unusual, says the company, and occurred in less than 1% of pathogenic variants over a 10-year period.</li><li>The WSJ report profiles several women in one family who underwent surgeries to prevent cancer, nearly all after taking Myriad tests. Years later, the women found out about the reclassification, which meant the mutation might not increase cancer risk.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528259\" data-linked=\"Myriad -8.6% after WSJ genetic test report\" data-tweet=\"$MYGN - Myriad -8.6% after WSJ genetic test report https://seekingalpha.com/news/3528259-myriadminus-8_6-after-wsj-genetic-test-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3528259-myriadminus-8_6-after-wsj-genetic-test-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528258\" data-ts=\"1577131471\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528258-cincinnati-bell-and-secureworks-among-tech-gainers-safe-t-group-and-digimarc-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cincinnati Bell and SecureWorks among Tech gainers; Safe-T Group and Digimarc among losers</a></h4><ul><li><b>Gainers: </b>Cincinnati Bell (NYSE:<a href='https://seekingalpha.com/symbol/CBB' title='Cincinnati Bell Inc.'>CBB</a>) <font color=\"green\">+35%</font>. SecureWorks (NASDAQ:<a href='https://seekingalpha.com/symbol/SCWX' title='SecureWorks Corp.'>SCWX</a>) <font color=\"green\">+15%</font>. Cambium Networks (NASDAQ:<a href='https://seekingalpha.com/symbol/CMBM' title='Cambium Networks Corporation'>CMBM</a>) <font color=\"green\">+15%</font>. DPW Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a>) <font color=\"green\">+14%</font>. CLPS (NASDAQ:<a href='https://seekingalpha.com/symbol/CLPS' title='CLPS Incorporation'>CLPS</a>) <font color=\"green\">+11%</font>.</li><li><b>Losers: </b>Safe-T Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SFET' title='Safe-T Group Ltd'>SFET</a>) <font color=\"red\">-24%</font>. Digimarc (NASDAQ:<a href='https://seekingalpha.com/symbol/DMRC' title='Digimarc Corporation'>DMRC</a>) <font color=\"red\">-11%</font>. Marin Software (NASDAQ:<a href='https://seekingalpha.com/symbol/MRIN' title='Marin Software Incorporated'>MRIN</a>) <font color=\"red\">-9%</font>. Phunware (NASDAQ:<a href='https://seekingalpha.com/symbol/PHUN' title='Phunware, Inc.'>PHUN</a>) <font color=\"red\">-8%</font>. SCWorx (NASDAQ:<a href='https://seekingalpha.com/symbol/WORX' title='SCWorx Corp.'>WORX</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528258\" data-linked=\"Cincinnati Bell and SecureWorks among Tech gainers; Safe-T Group and Digimarc among losers\" data-tweet=\"$CBB $SCWX $CMBM - Cincinnati Bell and SecureWorks among Tech gainers; Safe-T Group and Digimarc among losers https://seekingalpha.com/news/3528258-cincinnati-bell-and-secureworks-among-tech-gainers-safe-t-group-and-digimarc-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3528258-cincinnati-bell-and-secureworks-among-tech-gainers-safe-t-group-and-digimarc-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528251\" data-ts=\"1577128269\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLNO\" target=\"_blank\">SLNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528251-soleno-therapeuticsplus-20-oppenheimer-starts-outperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Soleno Therapeutics +20% as Oppenheimer starts at Outperform</a></h4><ul><li>Soleno Therapeutics (<a href='https://seekingalpha.com/symbol/SLNO' title='Soleno Therapeutics, Inc.'>SLNO</a> <font color=\"green\">+19.7%</font>) soars as much as 38% after Oppenheimer starts coverage with an <a href=\"https://thefly.com/thestreet/realmoney/index.php/SLNOid3010190/SLNO-Soleno-Therapeutics-initiated-with-an-Outperform-at-Oppenheimer\" target=\"_blank\">Outperform rating </a>and a $10 price target.</li><li>SLNO's DCCR has  demonstrated clinical proof-of-concept in Prader-Willi syndrome, and its  active ingredient has a long record of human safety, Oppy analyst Leland Gershell says.</li><li>With \"just\" a ~$65M enterprise value, the  analyst likes the stock's risk/reward and recommends building a  position ahead of the Phase 3 reveal in H1 2020.</li><li>SLNO's average <a href=\"https://seekingalpha.com/symbol/SLNO/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Bullish, while its <a href=\"https://seekingalpha.com/symbol/SLNO/ratings/quant-ratings\" target=\"_blank\">Quant Rating </a>is Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528251\" data-linked=\"Soleno Therapeutics +20% as Oppenheimer starts at Outperform\" data-tweet=\"$SLNO - Soleno Therapeutics +20% as Oppenheimer starts at Outperform https://seekingalpha.com/news/3528251-soleno-therapeuticsplus-20-oppenheimer-starts-outperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3528251-soleno-therapeuticsplus-20-oppenheimer-starts-outperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528250\" data-ts=\"1577128254\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAM\" target=\"_blank\">BAM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528250-brookfield-assetminus-1_0-wsj-highlights-mall-risks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brookfield Asset -1.0% as WSJ highlights mall risks</a></h4><ul><li>Brookfield Asset Management's (<a href='https://seekingalpha.com/symbol/BAM' title='Brookfield Asset Management Inc.'>BAM</a> <font color='red'>-1%</font>) <font color=\"red\">slips 1.0% </font>after the <em>Wall Street Journal</em> publishes an article pointing out that the alternative asset manager's bet on malls, through its acquisition GGP in August 2018,<a href=\"https://www.wsj.com/articles/brookfields-bet-on-malls-looks-riskier-than-ever-11577019601\" target=\"_blank\"> is looking riskier</a> than ever.</li><li>Since the acquisition, major mall tenants Sears Holding and Forever 21 have filed for bankruptcy, while the stocks of other major mall tenants, including Gap, Macy's, and J.C. Penney, sank after weak earnings reports.</li><li>Brookfield, though, believes that while there are probably too many malls in the U.S., many of the strongest ones will thrive.</li><li>Its strategy focuses on extracting more value from the properties by reconfiguring stores and redeveloping the land that surrounds them.</li><li>The company has $2.5B of projects underway to build residential complexes, office space, and hotels on the sites of nine of its malls and to remodel some of their existing retail space. Furthermore, it has identified $2.6B of longer-term projects.</li><li>To boost returns, Brookfield aims to sell the buildings that it's constructing on land around its malls to other investors. It projects that it can create a combined $1.8B in incremental value through the current and long-term projects it has identified.</li><li>The outcome of the strategy is still to be seen, of course.</li><li>Green Street Advisors estimates a 10% drop in the value of Brookfield's malls this year. Brookfield, though, disagrees with Green Street's analysis that almost half of its 113 malls rate as B+ or lower, saying that its average tenant sales per square foot is a relatively high $787.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528250\" data-linked=\"Brookfield Asset -1.0% as WSJ highlights mall risks\" data-tweet=\"$BAM - Brookfield Asset -1.0% as WSJ highlights mall risks https://seekingalpha.com/news/3528250-brookfield-assetminus-1_0-wsj-highlights-mall-risks?source=tweet\" data-url=\"https://seekingalpha.com/news/3528250-brookfield-assetminus-1_0-wsj-highlights-mall-risks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528249\" data-ts=\"1577128165\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UBER\" target=\"_blank\">UBER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528249-uber-wins-judge-strikes-down-cruising-cap\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Uber wins as judge strikes down cruising cap</a></h4><ul><li>Judge Lyle Frank of the Supreme Court of State of New York <a href=\"https://www.reuters.com/article/us-uber-new-york/in-win-for-uber-judge-strikes-down-new-york-citys-cruising-cap-idUSKBN1YR1WC\" target=\"_blank\">strikes down</a> a new rule limiting how much time ride-hail drivers can spend driving busy streets in Manhattan without passengers.</li><li>Judge Frank calls NYC's cruising cap \"arbitrary and capricious.\"</li><li>Uber (<a href='https://seekingalpha.com/symbol/UBER' title='Uber Technologies, Inc.'>UBER</a> <font color='green'>+1%</font>) sued the city over the rule, and shares are gaining after the decision.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528249\" data-linked=\"Uber wins as judge strikes down cruising cap\" data-tweet=\"$UBER - Uber wins as judge strikes down cruising cap https://seekingalpha.com/news/3528249-uber-wins-judge-strikes-down-cruising-cap?source=tweet\" data-url=\"https://seekingalpha.com/news/3528249-uber-wins-judge-strikes-down-cruising-cap\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528248\" data-ts=\"1577127956\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528248-seadrill-and-apache-among-energy-materials-gainers-new-concept-energy-and-mammoth-energy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seadrill and Apache among Energy/Materials gainers; New Concept Energy and Mammoth Energy Services among losers</a></h4><ul><li><b>Gainers: </b>Seadrill (NYSE:<a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited'>SDRL</a>) <font color=\"green\">+33%</font>. Apache (NYSE:<a href='https://seekingalpha.com/symbol/APA' title='Apache Corporation'>APA</a>) <font color=\"green\">+16%</font>. Chaparral Energy (NYSE:<a href='https://seekingalpha.com/symbol/CHAP' title='Chaparral Energy, Inc.'>CHAP</a>) <font color=\"green\">+14%</font>. Covia (NYSE:<a href='https://seekingalpha.com/symbol/CVIA' title='Covia Holdings Corporation'>CVIA</a>) <font color=\"green\">+12%</font>. Coeur Mining (NYSE:<a href='https://seekingalpha.com/symbol/CDE' title='Coeur Mining, Inc.'>CDE</a>) <font color=\"green\">+10%</font>.</li><li><b>Losers: </b>New Concept Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a>) <font color=\"red\">-14%</font>. Mammoth Energy Services (NASDAQ:<a href='https://seekingalpha.com/symbol/TUSK' title='Mammoth Energy Services, Inc.'>TUSK</a>) <font color=\"red\">-8%</font>. IKONICS (NASDAQ:<a href='https://seekingalpha.com/symbol/IKNX' title='IKONICS Corporation'>IKNX</a>) <font color=\"red\">-7%</font>. Evolution Petroleum (NYSEMKT:<a href='https://seekingalpha.com/symbol/EPM' title='Evolution Petroleum Corporation'>EPM</a>) <font color=\"red\">-7%</font>. Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528248\" data-linked=\"Seadrill and Apache among Energy/Materials gainers; New Concept Energy and Mammoth Energy Services among losers\" data-tweet=\"$SDRL $APA $CHAP - Seadrill and Apache among Energy/Materials gainers; New Concept Energy and Mammoth Energy Services among losers https://seekingalpha.com/news/3528248-seadrill-and-apache-among-energy-materials-gainers-new-concept-energy-and-mammoth-energy?source=tweet\" data-url=\"https://seekingalpha.com/news/3528248-seadrill-and-apache-among-energy-materials-gainers-new-concept-energy-and-mammoth-energy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528302\" data-ts=\"1577127397\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MITO\" target=\"_blank\">MITO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528302-stealth-bio-cut-to-neutral-h-c-wainwright-after-pmm-trial-failure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stealth Bio cut to Neutral at H.C. Wainwright after PMM trial failure</a></h4><ul><li>Stealth Biotherapeutics (<a href='https://seekingalpha.com/symbol/MITO' title='Stealth BioTherapeutics Corp'>MITO</a> <font color='red'>-6.3%</font>) sinks to a YTD low after H.C. Wainwright <a href=\"https://thefly.com/thestreet/realmoney/index.php/MITOid3010214/MITO-Stealth-Biotherapeutics-downgraded-to-Neutral-from-Buy-at-HC-Wainwright\" target=\"_blank\">downgrades</a> shares to Neutral from Buy with a $5 price target, slashed from $21, after the Phase 3 clinical trial of elamipretide in primary mitochondrial myopathy failed to meet its primary efficacy endpoints.</li><li>The <a href=\"https://seekingalpha.com/news/3527718-stealth-bios-elamipretide-flunks-late-stage-pmm-study\" target=\"_blank\">Phase 3 failure</a> is disappointing since elamipretide improved functional performance and patient reported outcomes in Phase 1 and Phase 2  studies, says Wainwright's Yi Chen.</li><li>Since there are no  alternative objective endpoints to measure efficacy in PMM patients, Chen thinks Stealth may not  further pursue the PMM indication, which comprised most of his  original valuation of the company.</li><li>MITO's average <a href=\"https://seekingalpha.com/symbol/MITO/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Bullish, and its <a href=\"https://seekingalpha.com/symbol/MITO/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors Rating</a> is Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528302\" data-linked=\"Stealth Bio cut to Neutral at H.C. Wainwright after PMM trial failure\" data-tweet=\"$MITO - Stealth Bio cut to Neutral at H.C. Wainwright after PMM trial failure https://seekingalpha.com/news/3528302-stealth-bio-cut-to-neutral-h-c-wainwright-after-pmm-trial-failure?source=tweet\" data-url=\"https://seekingalpha.com/news/3528302-stealth-bio-cut-to-neutral-h-c-wainwright-after-pmm-trial-failure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528246\" data-ts=\"1577126842\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528246-secureworksplus-14-dell-weighs-acquisition-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SecureWorks +14% as Dell weighs acquisition - report</a></h4><ul><li>SecureWorks (NASDAQ:<a href='https://seekingalpha.com/symbol/SCWX' title='SecureWorks Corp.'>SCWX</a>) gains after <a href=\"https://www.bloomberg.com/technology\" target=\"_blank\">Bloomberg sources</a> say Dell (NYSE:<a href='https://seekingalpha.com/symbol/DELL' title='Dell Technologies Inc.'>DELL</a>) could purchase the remaining outstanding shares of SCWX that Dell doesn't already own. Dell would then consolidate the business.</li><li>Dell currently owns about 86% of SecureWorks and holds over 98% of the voting power.</li><li>The acquisition plan, which is in the early stages and could still change, veers from Dell's earlier idea to sell its stake in the company.</li><li>SCWX shares are <font color=\"green\">up 13.9%</font> to $17.29.</li><li>Post updated with additional information.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528246\" data-linked=\"SecureWorks +14% as Dell weighs acquisition - report\" data-tweet=\"$SCWX $DELL - SecureWorks +14% as Dell weighs acquisition - report https://seekingalpha.com/news/3528246-secureworksplus-14-dell-weighs-acquisition-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3528246-secureworksplus-14-dell-weighs-acquisition-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528301\" data-ts=\"1577125439\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REGI\" target=\"_blank\">REGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528301-renewable-energy-target-hiked-to-58-bws-on-btc-benefits\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Renewable Energy target hiked to $58 at BWS on BTC benefits</a></h4><ul><li>Renewable Energy (<a href='https://seekingalpha.com/symbol/REGI' title='Renewable Energy Group, Inc.'>REGI</a> <font color=\"green\">+6.5%</font>) rallies to its highest level in nearly 10 months as BWS Financial maintains its Buy rating and <a href=\"https://thefly.com/thestreet/realmoney/index.php/REGIid3010351/REGI-Renewable-Energy-price-target-raised-to--from--at-BWS-Financial\" target=\"_blank\">raises its stock price target to $58</a> from $31, after the Congressional budget was amended to include the biodiesel tax  credit.</li><li>BMW analyst Hamed Khorsand estimates REGI should receive $500M in the next three months plus $900M  over the remaining three years of the current extension and retroactive approval of the BTC, which he says possibly could use the cash to buy  back debt and stock.</li><li>REGI's average <a href=\"https://seekingalpha.com/symbol/REGI/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> and <a href=\"https://seekingalpha.com/symbol/REGI/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> are Bullish, while its <a href=\"https://seekingalpha.com/symbol/REGI/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528301\" data-linked=\"Renewable Energy target hiked to $58 at BWS on BTC benefits\" data-tweet=\"$REGI - Renewable Energy target hiked to $58 at BWS on BTC benefits https://seekingalpha.com/news/3528301-renewable-energy-target-hiked-to-58-bws-on-btc-benefits?source=tweet\" data-url=\"https://seekingalpha.com/news/3528301-renewable-energy-target-hiked-to-58-bws-on-btc-benefits\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528236\" data-ts=\"1577124239\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528236-banco-bbva-argentina-and-grupo-financiero-galicia-among-financials-gainers-yintech-investment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Banco BBVA Argentina and Grupo Financiero Galicia among Financials gainers; Yintech Investment and Genworth Financial among losers</a></h4><ul><li><b>Gainers: </b>Banco BBVA Argentina (NYSE:<a href='https://seekingalpha.com/symbol/BBAR' title='Banco BBVA Argentina S.A.'>BBAR</a>) <font color=\"green\">+9%</font>. Grupo Financiero Galicia (NASDAQ:<a href='https://seekingalpha.com/symbol/GGAL' title='Grupo Financiero Galicia S.A.'>GGAL</a>) <font color=\"green\">+8%</font>. Kingsway Financial Services (NYSE:<a href='https://seekingalpha.com/symbol/KFS' title='Kingsway Financial Services Inc.'>KFS</a>) <font color=\"green\">+8%</font>. Grupo Supervielle (NYSE:<a href='https://seekingalpha.com/symbol/SUPV' title='Grupo Supervielle S.A.'>SUPV</a>) <font color=\"green\">+7%</font>. Oportun Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/OPRT' title='Oportun Financial Corporation'>OPRT</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Yintech Investment (NASDAQ:<a href='https://seekingalpha.com/symbol/YIN' title='Yintech Investment Holdings Limited'>YIN</a>) <font color=\"red\">-6%</font>. Genworth Financial (NYSE:<a href='https://seekingalpha.com/symbol/GNW' title='Genworth Financial, Inc.'>GNW</a>) <font color=\"red\">-5%</font>. Pennsylvania Real Estate Investment Trust (NYSE:<a href='https://seekingalpha.com/symbol/PEI' title='Pennsylvania Real Estate Investment Trust'>PEI</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528236\" data-linked=\"Banco BBVA Argentina and Grupo Financiero Galicia among Financials gainers; Yintech Investment and Genworth Financial among losers\" data-tweet=\"$BBAR $GGAL $KFS - Banco BBVA Argentina and Grupo Financiero Galicia among Financials gainers; Yintech Investment and Genworth Financial among losers https://seekingalpha.com/news/3528236-banco-bbva-argentina-and-grupo-financiero-galicia-among-financials-gainers-yintech-investment?source=tweet\" data-url=\"https://seekingalpha.com/news/3528236-banco-bbva-argentina-and-grupo-financiero-galicia-among-financials-gainers-yintech-investment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528234\" data-ts=\"1577124184\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPRT\" target=\"_blank\">OPRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528234-oportun-financialplus-6_6-btig-boosts-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oportun Financial +6.6% as BTIG boosts price target</a></h4><ul><li>Oportun Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/OPRT' title='Oportun Financial Corporation'>OPRT</a>) <font color=\"green\">gains 6.6%</font> after BTIG analyst Mark Palmer <a href=\"http://researchwiseny.btig.com/ResearchLibraryAnalec/DownloadResearch.aspx?E=cafdbk-b\" target=\"_blank\">raises</a> his price target on the stock to $27 from $22, as  a meeting with the company's CFO affirmed Palmer's constructive view of OPRT.</li><li>Reiterates buy recommendation.</li><li>CFO Jonathan Coblentz sees company benefiting from California rate cap law.</li><li>\"Unlike many of the other personal lenders in the state, who have been originating more than 350K loans per year with triple-digit annual percentage rates, OPRT as of the end of 3Q19 had an average APR of 34% and an average loan term of 32 months,\" Palmer writes.</li><li>OPRT launched a beta version of its new credit card, earlier than the Q1 2020 launch management had targeted.</li><li>Notes that the company, currently offering personal loans in 12 states, is in talks regarding bank partnerships; management will provide an update during Q4 2019 report in February.</li><li><a href=\"https://seekingalpha.com/symbol/OPRT/ratings/sell-side-ratings\" target=\"_blank\">Sell-Side average rating</a> is Bullish (2 Very Bullish, Bullish).</li></ul><div class=\"tiny-share-widget\" data-id=\"3528234\" data-linked=\"Oportun Financial +6.6% as BTIG boosts price target\" data-tweet=\"$OPRT - Oportun Financial +6.6% as BTIG boosts price target https://seekingalpha.com/news/3528234-oportun-financialplus-6_6-btig-boosts-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3528234-oportun-financialplus-6_6-btig-boosts-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528230\" data-ts=\"1577124005\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528230-dixie-group-leads-industrial-gainers-aar-and-summit-materials-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dixie Group leads industrial gainers; AAR and Summit Materials among losers</a></h4><ul><li><b>Gainers: </b>The Dixie Group (NASDAQ:<a href='https://seekingalpha.com/symbol/DXYN' title='The Dixie Group, Inc.'>DXYN</a>) <font color=\"green\">+20%</font>. Charah Solutions (NYSE:<a href='https://seekingalpha.com/symbol/CHRA' title='Charah Solutions, Inc.'>CHRA</a>) <font color=\"green\">+16%</font>. Coda Octopus (NASDAQ:<a href='https://seekingalpha.com/symbol/CODA' title='Coda Octopus Group, Inc.'>CODA</a>) <font color=\"green\">+8%</font>. The LGL Group (NYSEMKT:<a href='https://seekingalpha.com/symbol/LGL' title='The LGL Group, Inc.'>LGL</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>Newater Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/NEWA' title='Newater Technology, Inc.'>NEWA</a>) <font color=\"red\">-20%</font>. Euro Tech (NASDAQ:<a href='https://seekingalpha.com/symbol/CLWT' title='Euro Tech Holdings Company Limited'>CLWT</a>) <font color=\"red\">-10%</font>. AAR (NYSE:<a href='https://seekingalpha.com/symbol/AIR' title='AAR Corp.'>AIR</a>) <font color=\"red\">-7%</font>. Summit Materials (NYSE:<a href='https://seekingalpha.com/symbol/SUM' title='Summit Materials, Inc.'>SUM</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528230\" data-linked=\"Dixie Group leads industrial gainers; AAR and Summit Materials among losers\" data-tweet=\"$DXYN $CHRA $CODA - Dixie Group leads industrial gainers; AAR and Summit Materials among losers https://seekingalpha.com/news/3528230-dixie-group-leads-industrial-gainers-aar-and-summit-materials-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3528230-dixie-group-leads-industrial-gainers-aar-and-summit-materials-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528217\" data-ts=\"1577122668\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528217-sdrl-itci-idra-and-otlk-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SDRL, ITCI, IDRA and OTLK among midday movers</a></h4><ul><li><strong>Gainers: </strong>Intra-Cellular Therapies (NASDAQ:<a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies, Inc.'>ITCI</a>) <font color=\"green\">+204%</font>.</li><li>Cassava Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SAVA' title='Cassava Sciences, Inc.'>SAVA</a>) <font color=\"green\">+69%</font>.</li><li>Microbot Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc.'>MBOT</a>) <font color=\"green\">+54%</font>.</li><li>Cabaletta Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/CABA' title='Cabaletta Bio, Inc.'>CABA</a>) <font color=\"green\">+39%</font>.</li><li>Cincinnati Bell (NYSE:<a href='https://seekingalpha.com/symbol/CBB' title='Cincinnati Bell Inc.'>CBB</a>) <font color=\"green\">+34%</font>.</li><li>Soleno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SLNO' title='Soleno Therapeutics, Inc.'>SLNO</a>) <font color=\"green\">+29%</font>.</li><li>Seadrill (NYSE:<a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited'>SDRL</a>) <font color=\"green\">+25%</font>.</li><li>AquaVenture (NYSE:<a href='https://seekingalpha.com/symbol/WAAS' title='AquaVenture Holdings Limited'>WAAS</a>) <font color=\"green\">+24%</font>.</li><li>Idera Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/IDRA' title='Idera Pharmaceuticals, Inc.'>IDRA</a>) <font color=\"green\">+23%</font>.</li><li>ObsEva (NASDAQ:<a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva SA'>OBSV</a>) <font color=\"green\">+20%</font>.</li><li><strong>Losers: </strong>Outlook Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/OTLK' title='Outlook Therapeutics, Inc.'>OTLK</a>) <font color=\"red\">-50%</font>.</li><li>Safe-T Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SFET' title='Safe-T Group Ltd'>SFET</a>) <font color=\"red\">-24%</font>.</li><li>Newater Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/NEWA' title='Newater Technology, Inc.'>NEWA</a>) <font color=\"red\">-20%</font>.</li><li>Nova LifeStyle (NASDAQ:<a href='https://seekingalpha.com/symbol/NVFY' title='Nova LifeStyle, Inc.'>NVFY</a>) <font color=\"red\">-19%</font>.</li><li>LAIX (NYSE:<a href='https://seekingalpha.com/symbol/LAIX' title='LAIX Inc.'>LAIX</a>) <font color=\"red\">-17%</font>.</li><li>Shineco (NASDAQ:<a href='https://seekingalpha.com/symbol/TYHT' title='Shineco, Inc.'>TYHT</a>) <font color=\"red\">-17%</font>.</li><li>New Concept Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a>) <font color=\"red\">-16%</font>.</li><li>Monopar Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MNPR' title='Monopar Therapeutics Inc.'>MNPR</a>) <font color=\"red\">-14%</font>.</li><li>Akerna (NASDAQ:<a href='https://seekingalpha.com/symbol/KERN' title='Akerna Corp.'>KERN</a>) <font color=\"red\">-14%</font>.</li><li>Armata Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/ARMP' title='Armata Pharmaceuticals, Inc.'>ARMP</a>) <font color=\"red\">-12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528217\" data-linked=\"SDRL, ITCI, IDRA and OTLK among midday movers\" data-tweet=\"$ITCI $SAVA $MBOT - SDRL, ITCI, IDRA and OTLK among midday movers https://seekingalpha.com/news/3528217-sdrl-itci-idra-and-otlk-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3528217-sdrl-itci-idra-and-otlk-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528205\" data-ts=\"1577121160\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RTN\" target=\"_blank\">RTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528205-raytheon-hits-record-high-after-raking-in-new-defense-contracts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raytheon hits record high after raking in new defense contracts</a></h4><ul><li>Raytheon (<a href='https://seekingalpha.com/symbol/RTN' title='Raytheon Company'>RTN</a> <font color='green'>+1.6%</font>) rallies to a fresh all-time high after <a href=\"https://www.defense.gov/Newsroom/Contracts/Contract/Article/2045874/\" target=\"_blank\">winning more than $3B in contracts</a> from the U.S. Department of Defense on Friday.</li><li>RTN received a <a href=\"https://seekingalpha.com/pr/17735689-missile-defense-agency-awards-raytheon-1-billion-standard-missileminus-3-iia-contract\" target=\"_blank\">~$1B contract</a> for Standard  Missile-6 full-rate production requirements to  include all up rounds, flight test rounds, spares and round design  agent.</li><li>The U.S. Navy awarded RTN a $1.95B modification contract for the  detail design and construction of four Multi Mission Surface Combatant  ships.</li><li>The company <a href=\"https://seekingalpha.com/pr/17735063-raytheon-building-additional-spyminus-6-radars-for-us-navy\" target=\"_blank\">also will build</a> two additional shipsets of SPY-6 radars under a $250M U.S. Navy contract, bringing its total of radar shipsets to DDG-51 Flight III destroyers to nine.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528205\" data-linked=\"Raytheon hits record high after raking in new defense contracts\" data-tweet=\"$RTN - Raytheon hits record high after raking in new defense contracts https://seekingalpha.com/news/3528205-raytheon-hits-record-high-after-raking-in-new-defense-contracts?source=tweet\" data-url=\"https://seekingalpha.com/news/3528205-raytheon-hits-record-high-after-raking-in-new-defense-contracts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528194\" data-ts=\"1577120706\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528194-bellring-brands-among-consumer-gainers-davidstea-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BellRing Brands among consumer gainers; DAVIDsTEA leads the losers</a></h4><ul><li><b>Gainers: </b>Superior Industries International (NYSE:<a href='https://seekingalpha.com/symbol/SUP' title='Superior Industries International, Inc.'>SUP</a>) <font color=\"green\">+9%</font>. RiceBran Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/RIBT' title='RiceBran Technologies'>RIBT</a>) <font color=\"green\">+8%</font>. BellRing Brands (NYSE:<a href='https://seekingalpha.com/symbol/BRBR' title='BellRing Brands, Inc.'>BRBR</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>DAVIDsTEA (NASDAQ:<a href='https://seekingalpha.com/symbol/DTEA' title='DAVIDsTEA Inc.'>DTEA</a>) <font color=\"red\">-11%</font>. China Automotive Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CAAS' title='China Automotive Systems, Inc.'>CAAS</a>) <font color=\"red\">-8%</font>. Naked Brand (NASDAQ:<a href='https://seekingalpha.com/symbol/NAKD' title='Naked Brand Group Limited'>NAKD</a>) <font color=\"red\">-7%</font>. Calyxt (NASDAQ:<a href='https://seekingalpha.com/symbol/CLXT' title='Calyxt, Inc.'>CLXT</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528194\" data-linked=\"BellRing Brands among consumer gainers; DAVIDsTEA leads the losers\" data-tweet=\"$SUP $RIBT $BRBR - BellRing Brands among consumer gainers; DAVIDsTEA leads the losers https://seekingalpha.com/news/3528194-bellring-brands-among-consumer-gainers-davidstea-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3528194-bellring-brands-among-consumer-gainers-davidstea-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528189\" data-ts=\"1577120157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOPS\" target=\"_blank\">TOPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528189-top-ships-announces-financing-for-recently-acquired-vessels\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Top Ships announces financing for recently acquired vessels</a></h4><ul><li>TOP Ships (<a href='https://seekingalpha.com/symbol/TOPS' title='Top Ships Inc.'>TOPS</a> <font color='red'>-4.6%</font>) has <a href=\"https://seekingalpha.com/pr/17735572-top-ships-inc-announces-financing-for-recently-acquired-two-newbuilding-vessels\" target=\"_blank\">entered into agreement</a> with a major Chinese financier in relation to a financing of up to $60.2M for its recently acquired vessels.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3527425-tops-shipsplus-6_9-after-acquisition-of-two-tanker-newbuildings\" target=\"_blank\">TOPS Ships +6.9% after acquisition of two tanker newbuildings</a> (Dec. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3528189\" data-linked=\"Top Ships announces financing for recently acquired vessels\" data-tweet=\"$TOPS - Top Ships announces financing for recently acquired vessels https://seekingalpha.com/news/3528189-top-ships-announces-financing-for-recently-acquired-vessels?source=tweet\" data-url=\"https://seekingalpha.com/news/3528189-top-ships-announces-financing-for-recently-acquired-vessels\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528187\" data-ts=\"1577119280\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VSBN\" target=\"_blank\">VSBN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528187-vsb-bancorpplus-46-northfield-to-acquire-in-62_9m-stock-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VSB Bancorp +46% as Northfield to acquire in $62.9M stock deal</a></h4><ul><li>VSB Bancorp (<a href='https://seekingalpha.com/symbol/VSBN' title='VSB Bancorp, Inc.'>OTC:VSBN</a>) <font color=\"green\">surges 46%</font> after Northfield Bancorp (<a href='https://seekingalpha.com/symbol/NFBK' title='Northfield Bancorp, Inc. &#40;Staten Island, NY&#41;'>NFBK</a> <font color='red'>-1.5%</font>)<a href=\"https://seekingalpha.com/pr/17735645-northfield-bancorp-inc-to-acquire-vsb-bancorp-inc-expanding-staten-island-franchise\" target=\"_blank\"> agrees to acquire</a> VSB for ~$62.9M of NFBK common stock.</li><li>The price for VSB shareholders is fixed at $33.30 per share, subject to a 5% collar; price represents a 51% premium to VSBN's closing price on Friday.</li><li>The deal will strengthen NFBK's presence in the Staten Island, NY, market; lower funding costs with ~325M of deposits, add total loans of ~$157M with an average yield of 5.77%, and create economies of scale, NFBK said.</li><li>Sees deal 8.5% accretive to NFBK's 2021 EPS and less than 2.5% dilutive to tangible book value per share at closing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528187\" data-linked=\"VSB Bancorp +46% as Northfield to acquire in $62.9M stock deal\" data-tweet=\"$VSBN $NFBK - VSB Bancorp +46% as Northfield to acquire in $62.9M stock deal https://seekingalpha.com/news/3528187-vsb-bancorpplus-46-northfield-to-acquire-in-62_9m-stock-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3528187-vsb-bancorpplus-46-northfield-to-acquire-in-62_9m-stock-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528184\" data-ts=\"1577118347\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528184-musk-trolls-bears\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Musk trolls the bears</a></h4><ul><li>\"Whoa ... the stock is so high lol,\" <a href=\"https://twitter.com/elonmusk/status/1209142364473843713\" target=\"_blank\">tweeted Elon Musk</a> minutes ago.</li><li>That tweet could have come at any number of points during Tesla's (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) remarkable run over the past few months, but Musk waited until the price tripped the famed \"funding secured\" $420 level.</li><li>At current pixel time, Tesla is <font color=\"green\">up 3.55%</font> on the session to exactly $420.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3528051-tesla-to-take-new-1_4b-loan-for-shanghai-plant\" target=\"_blank\">Tesla to take new $1.4B loan for Shanghai plant</a> (Dec. 23)</li></ul><div class=\"tiny-share-widget\" data-id=\"3528184\" data-linked=\"Musk trolls the bears\" data-tweet=\"$TSLA - Musk trolls the bears https://seekingalpha.com/news/3528184-musk-trolls-bears?source=tweet\" data-url=\"https://seekingalpha.com/news/3528184-musk-trolls-bears\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>249&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528180\" data-ts=\"1577117618\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ITCI\" target=\"_blank\">ITCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528180-intra-cellular-drug-approval-augurs-well-for-cns-stocks-stifel-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intra-Cellular drug approval augurs well for CNS stocks, Stifel says</a></h4><ul><li>The FDA's approval of Intra-Cellular Therapies' (<a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies, Inc.'>ITCI</a> <font color='green'>+191.6%</font>) schizophrenia drug bodes well for other companies with therapies for the central nervous system, writes Stifel analyst Paul Matteis.</li><li>He points to Sage Therapeutics (<a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics, Inc.'>SAGE</a> <font color='red'>-1.1%</font>), Acadia Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ACAD' title='ACADIA Pharmaceuticals Inc.'>ACAD</a> <font color='red'>-1.7%</font>), Karuna Therapeutics (<a href='https://seekingalpha.com/symbol/KRTX' title='Karuna Therapeutics, Inc.'>KRTX</a> <font color='red'>-7.3%</font>), and, to some extent, Biogen (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color='green'>+0.6%</font>).</li><li>The recent approval shows that regulators will \"often look at a mixed efficacy package in CNS through a 'glass half full lens',\" given that ITCI's drug failed in one of the two Phase 3 studies, he writes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528180\" data-linked=\"Intra-Cellular drug approval augurs well for CNS stocks, Stifel says\" data-tweet=\"$ITCI $SAGE $ACAD - Intra-Cellular drug approval augurs well for CNS stocks, Stifel says https://seekingalpha.com/news/3528180-intra-cellular-drug-approval-augurs-well-for-cns-stocks-stifel-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3528180-intra-cellular-drug-approval-augurs-well-for-cns-stocks-stifel-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528173\" data-ts=\"1577116848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528173-microbot-medical-among-healthcare-gainers-outlook-therapeutics-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microbot Medical among healthcare gainers; Outlook Therapeutics leads losers</a></h4><ul><li><b>Gainers: </b>Intra-Cellular Therapies (NASDAQ:<a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies, Inc.'>ITCI</a>) <font color=\"green\">+173%</font>. Microbot Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc.'>MBOT</a>) <font color=\"green\">+66%</font>. Cassava Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SAVA' title='Cassava Sciences, Inc.'>SAVA</a>) <font color=\"green\">+51%</font>. Soleno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SLNO' title='Soleno Therapeutics, Inc.'>SLNO</a>) <font color=\"green\">+33%</font>. Cabaletta Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/CABA' title='Cabaletta Bio, Inc.'>CABA</a>) <font color=\"green\">+22%</font>.</li><li><b>Losers: </b>Outlook Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/OTLK' title='Outlook Therapeutics, Inc.'>OTLK</a>) <font color=\"red\">-53%</font>. Shineco (NASDAQ:<a href='https://seekingalpha.com/symbol/TYHT' title='Shineco, Inc.'>TYHT</a>) <font color=\"red\">-18%</font>. Monopar Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MNPR' title='Monopar Therapeutics Inc.'>MNPR</a>) <font color=\"red\">-14%</font>. Vascular Biogenics (NASDAQ:<a href='https://seekingalpha.com/symbol/VBLT' title='Vascular Biogenics Ltd.'>VBLT</a>) <font color=\"red\">-13%</font>. Armata Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/ARMP' title='Armata Pharmaceuticals, Inc.'>ARMP</a>) <font color=\"red\">-11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528173\" data-linked=\"Microbot Medical among healthcare gainers; Outlook Therapeutics leads losers\" data-tweet=\"$ITCI $MBOT $SAVA - Microbot Medical among healthcare gainers; Outlook Therapeutics leads losers https://seekingalpha.com/news/3528173-microbot-medical-among-healthcare-gainers-outlook-therapeutics-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3528173-microbot-medical-among-healthcare-gainers-outlook-therapeutics-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528171\" data-ts=\"1577116756\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528171-citi-sees-skyworks-potential-broadcom-unit-buyer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi sees Skyworks as potential Broadcom unit buyer</a></h4><ul><li>Citi adds a positive catalyst watch to Skyworks Solutions (<a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a> <font color='green'>+0.9%</font>), seeing the company as a potential buyer for Broadcom's (<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Inc.'>AVGO</a> <font color='green'>+0.3%</font>) RF semiconductor business.</li><li>Citi: \"A deal for SWKS could be highly or 46% accretive to C21 EPS assuming $10B valuation.\"</li><li>Related: Last week, <a href=\"https://seekingalpha.com/news/3527200-broadcom-wants-buyer-for-rf-unit-wsj\" target=\"_blank\">WSJ sources</a> said Broadcom was looking for a buyer for the unit, which had $2.2B in revenue in FY19.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528171\" data-linked=\"Citi sees Skyworks as potential Broadcom unit buyer\" data-tweet=\"$SWKS $AVGO - Citi sees Skyworks as potential Broadcom unit buyer https://seekingalpha.com/news/3528171-citi-sees-skyworks-potential-broadcom-unit-buyer?source=tweet\" data-url=\"https://seekingalpha.com/news/3528171-citi-sees-skyworks-potential-broadcom-unit-buyer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528167\" data-ts=\"1577116378\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528167-lyftminus-5_3-keybanc-sees-stagnating-user-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lyft -5.3% as KeyBanc sees stagnating user growth</a></h4><ul><li>KeyBanc analyst Andy Hargreaves says new riders for Lyft (NASDAQ:<a href='https://seekingalpha.com/symbol/LYFT' title='Lyft, Inc.'>LYFT</a>) and Uber (NYSE:<a href='https://seekingalpha.com/symbol/UBER' title='Uber Technologies, Inc.'>UBER</a>) combined declined 2% in Q3, the first Y/Y new customer drop since KeyBanc started tracking the data.</li><li>The analyst says Lyft's slowdown probably reflects more \"limited geographical expansion and less aggressive promotions.\" The growth could materially slow unless Lyft broadens its use cases, which KeyBanc says \"will be difficult.\"</li><li>Lyft shares are <font color=\"red\">down 5.3%</font> to $45.38. UBER is <font color=\"red\">down 0.8%</font> to $30.20.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528167\" data-linked=\"Lyft -5.3% as KeyBanc sees stagnating user growth\" data-tweet=\"$LYFT $UBER - Lyft -5.3% as KeyBanc sees stagnating user growth https://seekingalpha.com/news/3528167-lyftminus-5_3-keybanc-sees-stagnating-user-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3528167-lyftminus-5_3-keybanc-sees-stagnating-user-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528138\" data-ts=\"1577112713\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528138-roku-walmart-launch-smart-tvs-in-mexico\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roku, Walmart launch smart TVs in Mexico</a></h4><ul><li>Roku (<a href='https://seekingalpha.com/symbol/ROKU' title='Roku, Inc.'>ROKU</a> <font color='green'>+1.4%</font>) <a href=\"https://seekingalpha.com/pr/17735525-walmart-and-roku-launch-new-atvio-roku-tv-lineup-in-mexico\" target=\"_blank\">launches </a>the new Atvio Roku TV lineup of smart TVs exclusively at Walmart (<a href='https://seekingalpha.com/symbol/WMT' title='Walmart Inc.'>WMT</a> <font color='red'>-0.1%</font>) stores in Mexico.</li><li>The line includes a 32-inch HD screen model and 50- and 55-inch UHD screen models. Prices start at 3,499 pesos.</li><li>The devices will launch in the upcoming weeks.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528138\" data-linked=\"Roku, Walmart launch smart TVs in Mexico\" data-tweet=\"$ROKU $WMT - Roku, Walmart launch smart TVs in Mexico https://seekingalpha.com/news/3528138-roku-walmart-launch-smart-tvs-in-mexico?source=tweet\" data-url=\"https://seekingalpha.com/news/3528138-roku-walmart-launch-smart-tvs-in-mexico\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528136\" data-ts=\"1577112364\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DEAC\" target=\"_blank\">DEAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528136-spac-deal-draftkings-going-public-3_3b-valuation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SPAC deal has DraftKings going public at $3.3B valuation</a></h4><ul><li>Diamond Eagle Acquisition (NASDAQ:<a href='https://seekingalpha.com/symbol/DEAC' title='Diamond Eagle Acquisition Corp.'>DEAC</a>) <font color=\"green\">jumps 5.6%</font> after the special purpose acquisition company controlled by former Hollywood exec Jeff Sagansky <a href=\"https://seekingalpha.com/pr/17735262-draftkings-to-become-public-company-creating-only-vertically-integrated-u-s-based-sports\" target=\"_blank\">agrees to buy</a> DraftKings (<a href='https://seekingalpha.com/symbol/DRAFT' title='DraftKings'>DRAFT</a>) alongside gaming tech giant SBTech, in a<a href=\"https://seekingalpha.com/filing/4744493\" target=\"_blank\"> $2.07B deal</a>.</li><li>They expect the combined company to have an equity market capitalization at closing of ~$3.3B and have over $500M of unrestricted cash on the balance sheet.</li><li>DiamondEagle plans to change its name to DraftKings Inc., reincorporate in Nevada, and remain Nasdaq-listed under a new ticker symbol; sees deal closing in H1 2020.</li><li>Institutional investors have committed to a private investment of $304M in class A common stock of the combined company that will close at the same time as the business combination and, subject to any redemptions by DEAC stockholders, there is $400M currently held in Diamond Eagle's trust account.</li><li><a href=\"http://eagleinvestmentpartners.com/\" target=\"_blank\">Conference call</a> at 11:00 AM ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528136\" data-linked=\"SPAC deal has DraftKings going public at $3.3B valuation\" data-tweet=\"$DEAC $DRAFT - SPAC deal has DraftKings going public at $3.3B valuation https://seekingalpha.com/news/3528136-spac-deal-draftkings-going-public-3_3b-valuation?source=tweet\" data-url=\"https://seekingalpha.com/news/3528136-spac-deal-draftkings-going-public-3_3b-valuation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528131\" data-ts=\"1577111368\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SDRL\" target=\"_blank\">SDRL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528131-seadrill-shoots-higher-rig-wins-north-sea-work\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seadrill shoots higher as rig wins North Sea work</a></h4><ul><li>Seadrill (NYSE:<a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited'>SDRL</a>) <font color=\"green\">+29.6%</font> pre-market on news that Norwegian oil company Var Energi has <a href=\"https://www.offshoreenergytoday.com/var-energi-selects-seadrill-rig-for-balder-future-drilling/\" target=\"_blank\">chartered its <em>West Phoenix</em> offshore drilling rig</a> for operations at the Balder field in the North Sea.</li><li>SDRL says it expects the total contract value for the firm portion of the contract at ~$302M, with start-up anticipated at the end of Q2 2021 and running through Q3 2023; Bassoe Offshore calculates a dayrate of $360K.</li><li>Var Energi's Balder Future project is a part of the Balder X project, with targeted recovery of 200M barrels of additional reserves from  the Balder-Ringhorne area in the North Sea.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528131\" data-linked=\"Seadrill shoots higher as rig wins North Sea work\" data-tweet=\"$SDRL - Seadrill shoots higher as rig wins North Sea work https://seekingalpha.com/news/3528131-seadrill-shoots-higher-rig-wins-north-sea-work?source=tweet\" data-url=\"https://seekingalpha.com/news/3528131-seadrill-shoots-higher-rig-wins-north-sea-work\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528129\" data-ts=\"1577111197\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528129-nbcuniversal-and-lionsgate-reach-deals-for-xfinity-peacock\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NBCUniversal and Lionsgate reach deals for Xfinity, Peacock</a></h4><ul><li>Comcast NBCUniversal (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCSA' title='Comcast Corporation'>CMCSA</a>) and Starz (<a href='https://seekingalpha.com/symbol/LGF.A' title='Lions Gate Entertainment Corp.'>LGF.A</a>,<a href='https://seekingalpha.com/symbol/LGF.B' title='Lions Gate Entertainment Corp.'>LGF.B</a>) <a href=\"https://seekingalpha.com/pr/17735536-comcast-nbcuniversal-and-starz-reach-comprehensive-long-term-agreement\" target=\"_blank\">enter</a> into a long-term agreement for the continued carriage of Starz networks on Xfinity TV.</li><li>The agreement also includes a new content deal that allows NBCUniversal to license Lionsgate content for its Peacock streaming service, which will launch in April 2020.</li><li>Financial terms weren't disclosed.</li><li>Lionsgate shares are <font color=\"green\">up 7.9%</font> to $10.83.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528129\" data-linked=\"NBCUniversal and Lionsgate reach deals for Xfinity, Peacock\" data-tweet=\"$CMCSA $LGF.A $LGF.B - NBCUniversal and Lionsgate reach deals for Xfinity, Peacock https://seekingalpha.com/news/3528129-nbcuniversal-and-lionsgate-reach-deals-for-xfinity-peacock?source=tweet\" data-url=\"https://seekingalpha.com/news/3528129-nbcuniversal-and-lionsgate-reach-deals-for-xfinity-peacock\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528125\" data-ts=\"1577110790\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528125-sdrl-apa-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SDRL, APA among premarket gainers</a></h4><ul><li>Intra-Cellular Therapies (NASDAQ:<a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies, Inc.'>ITCI</a>) <font color=\"green\">+89%</font> <a href=\"https://seekingalpha.com/news/3528085-intra-cellular-therapiesplus-86-premarket-after-caplyta-approved-fda\" target=\"_blank\">after</a> Caplyta approved by FDA.</li><li>Cincinnati Bell (NYSE:<a href='https://seekingalpha.com/symbol/CBB' title='Cincinnati Bell Inc.'>CBB</a>) <font color=\"green\">+32%</font> on being <a href=\"https://seekingalpha.com/news/3528069-brookfield-infrastructure-to-buy-cincinnati-bell-in-2_6b-deal\" target=\"_blank\">acquired</a> by Brookfield Infrastructure</li><li>Seadrill (NYSE:<a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited'>SDRL</a>) <font color=\"green\">+27%</font>.</li><li>YayYo (NASDAQ:<a href='https://seekingalpha.com/symbol/YAYO' title='YayYo, Inc.'>YAYO</a>) <font color=\"green\">+21%</font> after <a href=\"https://seekingalpha.com/news/3528102-yayyo-reports-q3-results\" target=\"_blank\">Q3 results</a>.</li><li>Soleno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SLNO' title='Soleno Therapeutics, Inc.'>SLNO</a>) <font color=\"green\">+20%</font>.</li><li>DPW Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a>) <font color=\"green\">+19%</font> as <a href=\"https://seekingalpha.com/news/3528118-dpw-ceo-stocks-up-on-stock\" target=\"_blank\">CEO stocks up</a> on stock.</li><li>Microbot Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc.'>MBOT</a>) <font color=\"green\">+19%</font> on <a href=\"https://seekingalpha.com/news/3528099-microbot-launches-fully-disposable-robotic-system-for-endovascular-procedures\" target=\"_blank\">launching</a> fully disposable robotic system for endovascular procedures.</li><li>Cassava Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SAVA' title='Cassava Sciences, Inc.'>SAVA</a>) <font color=\"green\">+18%</font>.</li><li>Progenics Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PGNX' title='Progenics Pharmaceuticals, Inc.'>PGNX</a>) <font color=\"green\">+11%</font> on <a href=\"https://seekingalpha.com/news/3528076-progenicsplus-20-premarket-on-positive-pyl-data-in-prostate-cancer\" target=\"_blank\">positive</a> PyL data in prostate cancer.</li><li>Diamond Eagle Acquisition (NASDAQ:<a href='https://seekingalpha.com/symbol/DEACU' title='Diamond Eagle Acquisition Corp.'>DEACU</a>) <font color=\"green\">+10%</font> on <a href=\"https://seekingalpha.com/pr/17735262-draftkings-to-become-public-company-creating-only-vertically-integrated-u-s-based-sports\" target=\"_blank\">entering</a> into business combination agreement.</li><li>Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) <font color=\"green\">+9%</font> on <a href=\"https://seekingalpha.com/news/3528061-sareptaplus-13-premarket-on-srpminus-9001-deal-roche-outside-u-s\" target=\"_blank\">SRP-9001 deal</a> with Roche outside U.S.</li><li>Zosano Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ZSAN' title='Zosano Pharma Corporation'>ZSAN</a>) <font color=\"green\">+7%</font> on <a href=\"https://seekingalpha.com/news/3528096-zosanoplus-6-premarket-on-nda-submission-for-qtrypta\" target=\"_blank\">NDA submission</a> for Qtrypta.</li><li>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics, Inc.'>PTI</a>) <font color=\"green\">+7%</font>.</li><li>Akari Therapeutics, Plc (NASDAQ:<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics, Plc'>AKTX</a>) <font color=\"green\">+7% </font>on <a href=\"https://seekingalpha.com/news/3528116-akari-therapeuticsplus-7-premarket-on-initiating-late-stage-nomacopan-trail-in-pediatric-hsct\" target=\"_blank\">initiating</a> late-stage nomacopan trail in pediatric HSCT-TMA.</li><li>NewLink Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a>) <font color=\"green\">+6%</font>.</li><li>Apache (NYSE:<a href='https://seekingalpha.com/symbol/APA' title='Apache Corporation'>APA</a>) <font color=\"green\">+6%</font> as Total to <a href=\"https://seekingalpha.com/news/3528064-total-to-pay-100m-bonus-for-suriname-deal\" target=\"_blank\">pay</a> $100M bonus for Suriname deal.</li><li>Abeona Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a>) <font color=\"green\">+6%</font>.</li><li>Agile Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AGRX' title='Agile Therapeutics, Inc.'>AGRX</a>) <font color=\"green\">+5%</font>.</li><li>Stealth BioTherapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MITO' title='Stealth BioTherapeutics Corp'>MITO</a>) <font color=\"green\">+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528125\" data-linked=\"SDRL, APA among premarket gainers\" data-tweet=\"$ITCI $CBB $SDRL - SDRL, APA among premarket gainers https://seekingalpha.com/news/3528125-sdrl-apa-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3528125-sdrl-apa-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528122\" data-ts=\"1577110691\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OTLK\" target=\"_blank\">OTLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528122-outlook-down-63-premarket-on-issuing-warrant-amendment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Outlook down 63% premarket on issuing warrant amendment</a></h4><ul> <li>Outlook Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/OTLK' title='Outlook Therapeutics, Inc.'>OTLK</a>) has <a href=\"https://seekingalpha.com/pr/17735544-outlook-therapeutics-announces-warrant-amendment-and-restructuring-of-senior-secured-notes-in\" target=\"_blank\">amended</a> the Warrants issued in April 2019 to reduce the exercise price to $0.232 per warrant and allow for the immediate exercise.</li><li>The expiration date of the Warrants has been changed to 5:00 pm EST on December 24, 2019.</li><li>The transaction was done to eliminate the Warrants as they included anti-dilution protection, which negatively impacted the ability of the company to raise additional funds.</li>  <li>Separately, effective December 20, 2019, the Company issued  ~$7.6M new senior secured notes in exchange for ~$7.3M outstanding senior secured notes that were due on December 22, 2019 and originally issued in December 2016.</li><li>The New Notes bear interest at a rate of 12% per annum, have a maturity date of December 31, 2020, and can be extended at the Company\u2019s option to June 30, 2021.</li><li>Shares are down <font color=\"red\">63%</font> premarket.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3528122\" data-linked=\"Outlook down 63% premarket on issuing warrant amendment\" data-tweet=\"$OTLK - Outlook down 63% premarket on issuing warrant amendment https://seekingalpha.com/news/3528122-outlook-down-63-premarket-on-issuing-warrant-amendment?source=tweet\" data-url=\"https://seekingalpha.com/news/3528122-outlook-down-63-premarket-on-issuing-warrant-amendment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528120\" data-ts=\"1577110049\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528120-laix-acor-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LAIX, ACOR among premarket losers</a></h4><ul><li>Outlook Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/OTLK' title='Outlook Therapeutics, Inc.'>OTLK</a>) <font color=\"red\">-49%</font> on <a href=\"https://seekingalpha.com/pr/17735544-outlook-therapeutics-announces-warrant-amendment-and-restructuring-of-senior-secured-notes-in\" target=\"_blank\">announcing</a> warrant amendment and restructuring of senior secured notes.</li><li>DropCar (NASDAQ:<a href='https://seekingalpha.com/symbol/DCAR' title='DropCar, Inc.'>DCAR</a>) <font color=\"red\">-8%</font>.</li><li>LAIX (NYSE:<a href='https://seekingalpha.com/symbol/LAIX' title='LAIX Inc.'>LAIX</a>) <font color=\"red\">-7%</font>.</li><li>Acorda Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ACOR' title='Acorda Therapeutics, Inc.'>ACOR</a>) <font color=\"red\">-6%</font> on <a href=\"https://seekingalpha.com/news/3528058-acorda-launches-private-exchange-of-276m-convertible-debt-offering\" target=\"_blank\">launching</a> a private exchange of $276M convertible debt offering.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3528120\" data-linked=\"LAIX, ACOR among premarket losers\" data-tweet=\"$OTLK $DCAR $LAIX - LAIX, ACOR among premarket losers https://seekingalpha.com/news/3528120-laix-acor-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3528120-laix-acor-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528118\" data-ts=\"1577109881\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DPW\" target=\"_blank\">DPW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528118-dpw-ceo-stocks-up-on-stock\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DPW CEO stocks up on stock</a></h4><ul><li>DPW Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a>)<font color=\"green\"> surges 16%</font> in premarket trading after an entity controlled by DPW's CEO and Chairman Milton C. Ault, III, <a href=\"https://seekingalpha.com/pr/17735243-dpw-holdings-inc-announces-ault-company-inc-agreed-to-acquire-19_9-ownership-position-in\" target=\"_blank\">acquires </a>a 19.9% stake in DPW's common stock at $1.12 per share, or 1 cent higher than its closing price on Dec. 20.</li><li>In the past six months,<a href=\"https://seekingalpha.com/symbol/DPW/momentum/performance\" target=\"_blank\"> DPW's stock has declined </a>by 81%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528118\" data-linked=\"DPW CEO stocks up on stock\" data-tweet=\"$DPW - DPW CEO stocks up on stock https://seekingalpha.com/news/3528118-dpw-ceo-stocks-up-on-stock?source=tweet\" data-url=\"https://seekingalpha.com/news/3528118-dpw-ceo-stocks-up-on-stock\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528116\" data-ts=\"1577109796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKTX\" target=\"_blank\">AKTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528116-akari-therapeuticsplus-7-premarket-on-initiating-late-stage-nomacopan-trail-in-pediatric-hsct\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akari Therapeutics +7% premarket on initiating late-stage nomacopan trail in pediatric HSCT-TMA</a></h4><ul> <li>Akari Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics, Plc'>AKTX</a>) is up <font color=\"green\">7%</font> premarket on <a href=\"https://seekingalpha.com/pr/17735492-akari-therapeutics-announces-initiation-of-pivotal-phase-iii-trial-of-nomacopan-in-pediatric\" target=\"_blank\">announcing</a> that the FDA IND is open for its multicenter Phase III study for the treatment of pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy &#40;HSCT-TMA&#41; with nomacopan, allowing clinical sites to open in Q1 2020.</li><li>The company now looks forward to start the Phase III study of nomacopan in HSCT-TMA.</li>   <li>Additionally, data from Phase I/II atopic keratoconjunctivitis trial is expected in early 2020 and interim data from Phase III paroxysmal nocturnal hemoglobinuria trial is expected in H1 2020.</li>        </ul><div class=\"tiny-share-widget\" data-id=\"3528116\" data-linked=\"Akari Therapeutics +7% premarket on initiating late-stage nomacopan trail in pediatric HSCT-TMA\" data-tweet=\"$AKTX - Akari Therapeutics +7% premarket on initiating late-stage nomacopan trail in pediatric HSCT-TMA https://seekingalpha.com/news/3528116-akari-therapeuticsplus-7-premarket-on-initiating-late-stage-nomacopan-trail-in-pediatric-hsct?source=tweet\" data-url=\"https://seekingalpha.com/news/3528116-akari-therapeuticsplus-7-premarket-on-initiating-late-stage-nomacopan-trail-in-pediatric-hsct\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528110\" data-ts=\"1577109170\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TBPH\" target=\"_blank\">TBPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528110-pfizer-licenses-theravances-jak-inhibitors-for-skin-conditions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pfizer licenses Theravance&#39;s JAK inhibitors for skin conditions</a></h4><ul><li>Theravance Biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/TBPH' title='Theravance Biopharma, Inc.'>TBPH</a>) enters a global license pact with Pfizer (NYSE:<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>) for Theravance's preclinical program for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitors that can be rapidly metabolized.</li><li>Theravance will get up an upfront cash payment of $10M and will be eligible for up to an additional $240M in development and sales milestone payments from Pfizer.</li><li>In addition, Theravance Biopharma will be eligible to receive royalties on worldwide net sales of any potential products emerging from the program.</li><li>Pfizer <font color=\"green\">gains 0.4%</font> in premarket trading.</li><li>\"Topical JAK inhibitors that can be rapidly metabolized have potential to reach more patients with mild-to-moderate skin conditions, for whom treatment is currently limited,\" said Michael Vincent, chief scientific officer, Inflammation &amp; Immunology, Pfizer.</li><li>JAK inhibitors are currently approved for the treatment of a range of inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, myelofibrosis, and ulcerative colitis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528110\" data-linked=\"Pfizer licenses Theravance&#39;s JAK inhibitors for skin conditions\" data-tweet=\"$TBPH $PFE - Pfizer licenses Theravance&#39;s JAK inhibitors for skin conditions https://seekingalpha.com/news/3528110-pfizer-licenses-theravances-jak-inhibitors-for-skin-conditions?source=tweet\" data-url=\"https://seekingalpha.com/news/3528110-pfizer-licenses-theravances-jak-inhibitors-for-skin-conditions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528107\" data-ts=\"1577108802\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NEOG\" target=\"_blank\">NEOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528107-neogen-eps-misses-0_01-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neogen EPS misses by $0.01, misses on revenue</a></h4><ul><li>Neogen (NASDAQ:<a href='https://seekingalpha.com/symbol/NEOG' title='Neogen Corporation'>NEOG</a>): Q2 GAAP EPS of $0.31 <font color=\"red\">misses by $0.01</font>.</li><li>Revenue of $107.8M (+0.7% Y/Y) <font color=\"red\">misses by $2.13M</font>.</li><li>Shares <font color=\"green\">+2%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17735493-neogen-reports-second-quarter-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3528107\" data-linked=\"Neogen EPS misses by $0.01, misses on revenue\" data-tweet=\"$NEOG - Neogen EPS misses by $0.01, misses on revenue https://seekingalpha.com/news/3528107-neogen-eps-misses-0_01-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3528107-neogen-eps-misses-0_01-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528103\" data-ts=\"1577108226\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LCI\" target=\"_blank\">LCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528103-lannettplus-7_1-after-two-dosage-strengths-of-bac-capsules-approved\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lannett +7.1% after two dosage strengths of BAC capsules approved</a></h4><ul><li>Lannett (NYSE:<a href='https://seekingalpha.com/symbol/LCI' title='Lannett Company, Inc.'>LCI</a>) <font color=\"green\">gains 7.1%</font> in premarket trading after the <a href=\"https://seekingalpha.com/pr/17735252-lannett-receives-fda-approvals-for-two-dosage-strengths-of-butalbital-acetaminophen-and\" target=\"_blank\">FDA approves </a>ANDAs for two dosage strengths of butalbital, acetaminophen, and caffeine capsules.</li><li>The company has started marketing BAC capsules, USP, 50mg/300mg/40mg and BAC capsules, USP, 50 mg/325mg/40mg.</li><li>The two dosage strengths have a combined estimated IQVIA market value of ~$68.6M for the 12 months ending October 2019, although actual generic market values are expected to be lower.</li><li>LCI sees launching as many as 12 products in the next six months.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528103\" data-linked=\"Lannett +7.1% after two dosage strengths of BAC capsules approved\" data-tweet=\"$LCI - Lannett +7.1% after two dosage strengths of BAC capsules approved https://seekingalpha.com/news/3528103-lannettplus-7_1-after-two-dosage-strengths-of-bac-capsules-approved?source=tweet\" data-url=\"https://seekingalpha.com/news/3528103-lannettplus-7_1-after-two-dosage-strengths-of-bac-capsules-approved\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528099\" data-ts=\"1577107770\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBOT\" target=\"_blank\">MBOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528099-microbot-launches-fully-disposable-robotic-system-for-endovascular-procedures\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microbot launches fully disposable robotic system for endovascular procedures</a></h4><ul><li>Microbot Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc.'>MBOT</a>) <font color=\"green\">+6.1%</font> pre-market after unveiling what it says is the world's first <a href=\"https://seekingalpha.com/pr/17735289-microbot-medical-to-unveil-world-s-first-fully-disposable-robotic-system-for-endovascular\" target=\"_blank\">fully disposable robotic system</a> for use in neurovascular, cardiovascular and peripheral vascular procedures.</li><li>MBOT says the LIBERTY robotic system features a compact design with remote operation capabilities while reducing radiation exposure and physical strain to the physician, as well as the potential to eliminate the use of multiple consumables through its \"One &amp; Done\" capabilities.</li><li>The company says it will publicly display and demonstrate the product on Jan. 13 in San Francisco.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528099\" data-linked=\"Microbot launches fully disposable robotic system for endovascular procedures\" data-tweet=\"$MBOT - Microbot launches fully disposable robotic system for endovascular procedures https://seekingalpha.com/news/3528099-microbot-launches-fully-disposable-robotic-system-for-endovascular-procedures?source=tweet\" data-url=\"https://seekingalpha.com/news/3528099-microbot-launches-fully-disposable-robotic-system-for-endovascular-procedures\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528096\" data-ts=\"1577106999\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZSAN\" target=\"_blank\">ZSAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528096-zosanoplus-6-premarket-on-nda-submission-for-qtrypta\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zosano +6% premarket on NDA submission for Qtrypta</a></h4><ul> <li>Zosano Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ZSAN' title='Zosano Pharma Corporation'>ZSAN</a>) has <a href=\"https://seekingalpha.com/pr/17735393-zosano-announces-fda-submission-of-new-drug-application-for-qtrypta\" target=\"_blank\">submitted</a> a 505(b)(2) New Drug Application (\u201cNDA\u201d) for Qtrypta for the acute treatment of migraine.</li>         <li>The company expects to receive notification from the FDA confirming whether the submission was accepted for filing for substantive review in March 2020.</li>    <li>Shares are up <font color=\"green\">6%</font> premarket.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3528096\" data-linked=\"Zosano +6% premarket on NDA submission for Qtrypta\" data-tweet=\"$ZSAN - Zosano +6% premarket on NDA submission for Qtrypta https://seekingalpha.com/news/3528096-zosanoplus-6-premarket-on-nda-submission-for-qtrypta?source=tweet\" data-url=\"https://seekingalpha.com/news/3528096-zosanoplus-6-premarket-on-nda-submission-for-qtrypta\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528092\" data-ts=\"1577106680\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGTX\" target=\"_blank\">TGTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528092-tg-therapeutics-launches-50m-registered-direct-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TG Therapeutics launches $50M registered direct offering</a></h4><ul><li>TG Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a>) has <a href=\"https://seekingalpha.com/pr/17735332-tg-therapeutics-announces-50_0-million-registered-direct-public-offering-of-common-stock-to\" target=\"_blank\">entered</a> into a definitive agreement to sell ~5.4M shares of registered common stock at $9.20 per share, to a single institutional investor as a registered direct public offering. Proceeds from the sale are expected to be ~$50M.</li><li>Net proceeds will be used to fund the ongoing development and commercialization of ublituximab and umbralisib, for R&amp;D activities and for general corporate purposes.</li><li>Closing date is December 23, 2019.</li><li>Shares are down <font color=\"red\">2%</font> premarket.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3528092\" data-linked=\"TG Therapeutics launches $50M registered direct offering\" data-tweet=\"$TGTX - TG Therapeutics launches $50M registered direct offering https://seekingalpha.com/news/3528092-tg-therapeutics-launches-50m-registered-direct-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3528092-tg-therapeutics-launches-50m-registered-direct-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528086\" data-ts=\"1577106126\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPGN\" target=\"_blank\">OPGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528086-fda-clears-curetis-unyvero-lrt-for-bal-specimens-opgn-shares-up-13-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA clears Curetis&#39; Unyvero LRT for BAL specimens; OPGN shares up 13% premarket</a></h4><ul> <li>OpGen (NASDAQ:<a href='https://seekingalpha.com/symbol/OPGN' title='OpGen, Inc.'>OPGN</a>) is up <font color=\"green\">13%</font> premarket on the heels of an <a href=\"https://seekingalpha.com/pr/17735330-opgen-provides-update-on-curetis-group-business-receiving-u-s-fda-510-k-clearance-of-unyvero\" target=\"_blank\">update</a> on the business of Curetis GmbH.</li><li>On December 20, 2019 Curetis has received 510(k) clearance by the FDA to market its Unyvero LRT Lower Respiratory Tract Application Cartridge for use with bronchoalveolar lavage &#40;BAL&#41; samples to diagnose lower respiratory tract infections such as pneumonia.</li>      <li>OpGen and Curetis entered into <a href=\"https://seekingalpha.com/news/3496718-opgen-to-merge-curetis-n-v-shares-up-69-premarket\" target=\"_blank\">merger agreement</a> on September 4, 2019.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3528086\" data-linked=\"FDA clears Curetis&#39; Unyvero LRT for BAL specimens; OPGN shares up 13% premarket\" data-tweet=\"$OPGN - FDA clears Curetis&#39; Unyvero LRT for BAL specimens; OPGN shares up 13% premarket https://seekingalpha.com/news/3528086-fda-clears-curetis-unyvero-lrt-for-bal-specimens-opgn-shares-up-13-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3528086-fda-clears-curetis-unyvero-lrt-for-bal-specimens-opgn-shares-up-13-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528085\" data-ts=\"1577106074\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ITCI\" target=\"_blank\">ITCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528085-intra-cellular-therapiesplus-86-premarket-after-caplyta-approved-fda\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intra-Cellular Therapies +86% premarket after Caplyta approved by FDA</a></h4><ul><li>Intra-Cellular Therapies (NASDAQ:<a href='https://seekingalpha.com/symbol/ITCI' title='Intra-Cellular Therapies, Inc.'>ITCI</a>) <font color=\"green\">skyrockets 86%</font> in premarket trading after the FDA <a href=\"https://seekingalpha.com/pr/17735257-fda-approves-intra-cellular-therapies-novel-antipsychotic-caplyta-lumateperone-for-treatment\" target=\"_blank\">approves </a>its Caplyta (lumateperone) for the treatment of schizophrenia in adults.</li><li>ITCI expects Caplyta's commercial launch in late Q1 2020.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3525176-intra-cellular-up-10-ahead-of-presentation-of-lumateperone-data\" target=\"_blank\">Intra-Cellular up 10% ahead of presentation of lumateperone data</a> (Dec. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3528085\" data-linked=\"Intra-Cellular Therapies +86% premarket after Caplyta approved by FDA\" data-tweet=\"$ITCI - Intra-Cellular Therapies +86% premarket after Caplyta approved by FDA https://seekingalpha.com/news/3528085-intra-cellular-therapiesplus-86-premarket-after-caplyta-approved-fda?source=tweet\" data-url=\"https://seekingalpha.com/news/3528085-intra-cellular-therapiesplus-86-premarket-after-caplyta-approved-fda\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528083\" data-ts=\"1577105946\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MMM\" target=\"_blank\">MMM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528083-tusa-upgrade-gives-3m-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tusa upgrade gives 3M a boost</a></h4><ul><li>JPMorgan upgrades 3M (NYSE:<a href='https://seekingalpha.com/symbol/MMM' title='3M Company'>MMM</a>) to Neutral from Underweight with a price target of $150 (from $143).</li><li>While PFAS chemicals litigation remains a risk, the spotlight is turning towards fundamentals \"as the relative earnings revision curve is probably more stable now,\" according to analyst Stephen Tusa.</li><li>MMM <font color=\"green\">+1.1%</font> premarket</li><li>Source: Bloomberg First Word</li></ul><div class=\"tiny-share-widget\" data-id=\"3528083\" data-linked=\"Tusa upgrade gives 3M a boost\" data-tweet=\"$MMM - Tusa upgrade gives 3M a boost https://seekingalpha.com/news/3528083-tusa-upgrade-gives-3m-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3528083-tusa-upgrade-gives-3m-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528080\" data-ts=\"1577105542\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBTC\" target=\"_blank\">GBTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528080-bitcoin-bounce-continues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bitcoin bounce continues</a></h4><ul><li>Technicians were looking for another leg down after Bitcoin (<a href='https://seekingalpha.com/symbol/BTC-USD' title='Bitcoin USD'>BTC-USD</a>) fell and stayed below $7K a few days back, but the crypto leader has managed to put in a rally since.</li><li>Up modestly today, Bitcoin is currently changing hands at $7.58K - <font color=\"green\">ahead more than 15%</font> over the past few sessions.</li><li>The technicians are quiet this morning, but the next level some are looking at would be $7.9K.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528080\" data-linked=\"Bitcoin bounce continues\" data-tweet=\"$GBTC $BTC-USD - Bitcoin bounce continues https://seekingalpha.com/news/3528080-bitcoin-bounce-continues?source=tweet\" data-url=\"https://seekingalpha.com/news/3528080-bitcoin-bounce-continues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528076\" data-ts=\"1577105187\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PGNX\" target=\"_blank\">PGNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528076-progenicsplus-20-premarket-on-positive-pyl-data-in-prostate-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Progenics +20% premarket on positive PyL data in prostate cancer</a></h4><ul> <li>Progenics Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PGNX' title='Progenics Pharmaceuticals, Inc.'>PGNX</a>) is up <font color=\"green\">20%</font> premarket on announcing <a href=\"https://seekingalpha.com/pr/17735296-progenics-pharmaceuticals-announces-phase-3-condor-trial-of-pyl-in-prostate-cancer-achieved\" target=\"_blank\">positive top line results</a> from the Phase 3 CONDOR trial evaluating the diagnostic performance and clinical impact of PyL (<sup>18</sup>F-DCFPyL) in men with biochemical recurrence of prostate cancer.</li>    <li>The study enrolled 208 patients. The trial achieved its primary endpoint, with a correct localization rate of 84.8% to 87.0% among the three blinded independent readers.</li>  <li>Safety results showed PyL was well tolerated, consistent with the Phase 2 OSPREY trial results.</li>  <li>The Company plans to submit a NDA for PyL in H2 2020.</li>  <li>Additional results from the CONDOR trial are expected to be presented at an upcoming medical meeting.</li><li>PyL is PSMA-targeted small molecule positron emission tomography imaging agent designed to visualize prostate cancer.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3528076\" data-linked=\"Progenics +20% premarket on positive PyL data in prostate cancer\" data-tweet=\"$PGNX - Progenics +20% premarket on positive PyL data in prostate cancer https://seekingalpha.com/news/3528076-progenicsplus-20-premarket-on-positive-pyl-data-in-prostate-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3528076-progenicsplus-20-premarket-on-positive-pyl-data-in-prostate-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528075\" data-ts=\"1577105129\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROK\" target=\"_blank\">ROK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528075-tusa-downgrades-rockwell-to-underweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tusa downgrades Rockwell to Underweight</a></h4><ul><li>JPMorgan has downgraded Rockwell Automation (NYSE:<a href='https://seekingalpha.com/symbol/ROK' title='Rockwell Automation, Inc.'>ROK</a>) to Underweight from Neutral with a PT of $150, implying a 27% decrease from Friday's close.</li><li>Wall Street has \"baked in too much optimism\" for Rockwell's Q1 estimates, according to analyst Stephen Tusa, which views the stock as the name most exposed to a slowing PMI.</li><li>ROK <font color=\"red\">-1%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3528075\" data-linked=\"Tusa downgrades Rockwell to Underweight\" data-tweet=\"$ROK - Tusa downgrades Rockwell to Underweight https://seekingalpha.com/news/3528075-tusa-downgrades-rockwell-to-underweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3528075-tusa-downgrades-rockwell-to-underweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528074\" data-ts=\"1577105031\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WAAS\" target=\"_blank\">WAAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528074-aquaventureplus-19_5-on-1_1b-culligan-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AquaVenture +19.5% on $1.1B Culligan merger</a></h4><ul><li>Culligan will acquire AquaVenture (NYSE:<a href='https://seekingalpha.com/symbol/WAAS' title='AquaVenture Holdings Limited'>WAAS</a>) for $27.10 per share in cash, a 25% premium to Friday's closing price.</li><li>The transaction is valued at approximately $1.1B, including net debt.</li><li>AquaVenture will become a privately held company and join Culligan's consumer water service and solutions platform.</li><li>The deal is expected to close in April 2020.</li><li>WAAS shares are <font color=\"green\">up 19.5%</font> pre-market to $26.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528074\" data-linked=\"AquaVenture +19.5% on $1.1B Culligan merger\" data-tweet=\"$WAAS - AquaVenture +19.5% on $1.1B Culligan merger https://seekingalpha.com/news/3528074-aquaventureplus-19_5-on-1_1b-culligan-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3528074-aquaventureplus-19_5-on-1_1b-culligan-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528061\" data-ts=\"1577102578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528061-sareptaplus-13-premarket-on-srpminus-9001-deal-roche-ex-u-s\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sarepta +13% premarket on SRP-9001 deal with Roche ex-U.S.</a></h4><ul> <li>Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) is up <font color=\"green\">13%</font> premarket in response to its <a href=\"https://seekingalpha.com/pr/17735162-sarepta-therapeutics-announces-partnership-roche-in-territories-outside-united-states-for\" target=\"_blank\">licensing agreement</a> with Roche (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding AG'>OTCQX:RHHBY</a>), providing the latter exclusive ex-U.S. rights to SRP-9001, an investigational gene therapy for Duchenne muscular dystrophy &#40;DMD&#41;.</li><li>Under the terms of the deal, Sarepta will receive $1.15B upfront, up to $1.7B in milestones and mid-teen royalties on net sales. Roche will also make an equity investment in Sarepta.</li>        <li>Sarepta will be responsible for manufacturing and supply. Roche has an option to acquire ex-U.S. rights to certain future DMD-specific programs, in exchange for additional milestone payments, royalties and cost sharing.</li><li>The companies will equally share global development expenses. SRPT retains all rights to SRP-9001 in the U.S.</li>  <li>The agreement should close next quarter.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3528061\" data-linked=\"Sarepta +13% premarket on SRP-9001 deal with Roche ex-U.S.\" data-tweet=\"$SRPT $RHHBY - Sarepta +13% premarket on SRP-9001 deal with Roche ex-U.S. https://seekingalpha.com/news/3528061-sareptaplus-13-premarket-on-srpminus-9001-deal-roche-ex-u-s?source=tweet\" data-url=\"https://seekingalpha.com/news/3528061-sareptaplus-13-premarket-on-srpminus-9001-deal-roche-ex-u-s\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528056\" data-ts=\"1577100608\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528056-record-highs-in-store-open\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More record highs in store at the open</a></h4><ul><li>Wall Street futures are starting a holiday-shortened week <font color=\"green\">ahead by 0.2%</font>, on the back of easing geopolitical risks and China's plans to cut import tariffs for its trading partners.</li><li>\"The Phase 1 agreement and U.K. elections have cleared up tail risks, but the market is now transcending that euphoria,\" <a href=\"https://www.reuters.com/article/us-global-markets/global-shares-stall-near-record-high-as-year-draws-to-close-idUSKBN1YR04N?feedType=RSS&amp;feedName=businessNews\" target=\"_blank\">said</a> Stephen Innes, strategist at AxiTrader. \"With plenty of capital yet to be deployed, markets could even push significantly higher supported by the global growth rebound.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3528056\" data-linked=\"More record highs in store at the open\" data-tweet=\"More record highs in store at the open https://seekingalpha.com/news/3528056-record-highs-in-store-open?source=tweet\" data-url=\"https://seekingalpha.com/news/3528056-record-highs-in-store-open\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528047\" data-ts=\"1577092494\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAYRY\" target=\"_blank\">BAYRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528047-bayerplus-3_5-after-backing-in-glyphosate-suit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bayer +3.5% after backing in glyphosate suit</a></h4><ul><li>Bayer (<a href='https://seekingalpha.com/symbol/BAYRY' title='Bayer Aktiengesellschaft'>OTCPK:BAYRY</a>) started the week <font color=\"green\">up 3.5%</font> to \u20ac74/share in Frankfurt, touching their highest level in 14 months, after the U.S. government <a href=\"https://seekingalpha.com/news/3527977-trump-administration-backs-bayer-in-glyphosate-court-appeal\" target=\"_blank\">said</a> a $25M glyphosate decision against the company should be reversed.</li><li>Both the EPA and DOJ wrote in a friend of the court brief that a federal appeals court should reverse a lower court verdict finding the company liable in the case of a man who blamed Bayer's Roundup for his cancer.</li></ul><div class=\"tiny-share-widget\" data-id=\"3528047\" data-linked=\"Bayer +3.5% after backing in glyphosate suit\" data-tweet=\"$BAYRY $BAYZF - Bayer +3.5% after backing in glyphosate suit https://seekingalpha.com/news/3528047-bayerplus-3_5-after-backing-in-glyphosate-suit?source=tweet\" data-url=\"https://seekingalpha.com/news/3528047-bayerplus-3_5-after-backing-in-glyphosate-suit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3528044\" data-ts=\"1577088897\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FXI\" target=\"_blank\">FXI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3528044-china-to-cut-tariffs-on-range-of-goods\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China to cut tariffs on range of goods</a></h4><ul><li>China said it will <a href=\"http://www.wsj.com/articles/china-to-lower-tariffs-on-some-imports-in-2020-11577066316\" target=\"_blank\">reduce</a> tariffs from Jan. 1 on more than 850 goods, including frozen pork, high-tech components and vital medicines, leading the Shanghai Composite Index to <font color=\"red\">tumble 1.4%</font> overnight.</li><li>It will also cut import levies for more than 8,000 products for 23 countries and regions that have free-trade agreements with China, known as \"most favored nation\" rates.</li><li>While the tariff reduction is not directly linked to the American trade war, it will likely guarantee that the coming Phase One trade deal with the U.S. doesn't invite complaints from other trading partners.</li><li>Shanghai <font color=\"red\">-1.4%</font> to 2,963.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/FXI' title='iShares China Large-Cap ETF'>FXI</a>, <a href='https://seekingalpha.com/symbol/KWEB' title='KraneShares CSI China Internet ETF'>KWEB</a>, <a href='https://seekingalpha.com/symbol/CQQQ' title='Invesco China Technology ETF'>CQQQ</a>, <a href='https://seekingalpha.com/symbol/ASHR' title='Deutsche X-trackers Harvest CSI 300 China A-Shares ETF'>ASHR</a>, <a href='https://seekingalpha.com/symbol/YINN' title='Direxion Daily FTSE China Bull 3x Shares ETF'>YINN</a>, <a href='https://seekingalpha.com/symbol/TDF' title='Templeton Dragon Fund'>TDF</a>, <a href='https://seekingalpha.com/symbol/MCHI' title='iShares MSCI China ETF'>MCHI</a>, <a href='https://seekingalpha.com/symbol/EWH' title='iShares MSCI Hong Kong ETF'>EWH</a>, <a href='https://seekingalpha.com/symbol/KBA' title='KraneShares Bosera MSCI China A ETF'>KBA</a>, <a href='https://seekingalpha.com/symbol/CAF' title='Morgan Stanley China A Share Fund'>CAF</a>, <a href='https://seekingalpha.com/symbol/YANG' title='Direxion Daily FTSE China Bear 3x Shares ETF'>YANG</a>, <a href='https://seekingalpha.com/symbol/GXC' title='SPDR S&P China ETF'>GXC</a>, <a href='https://seekingalpha.com/symbol/TAO' title='Invesco China Real Estate ETF'>TAO</a>, <a href='https://seekingalpha.com/symbol/CYB' title='WisdomTree Chinese Yuan ETF'>CYB</a>, <a href='https://seekingalpha.com/symbol/CHIX' title='Global X Funds - Global X MSCI China Financials ETF'>CHIX</a>, <a href='https://seekingalpha.com/symbol/CHIQ' title='Global X China Consumer ETF'>CHIQ</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3528044\" data-linked=\"China to cut tariffs on range of goods\" data-tweet=\"$FXI $KWEB $CQQQ - China to cut tariffs on range of goods https://seekingalpha.com/news/3528044-china-to-cut-tariffs-on-range-of-goods?source=tweet\" data-url=\"https://seekingalpha.com/news/3528044-china-to-cut-tariffs-on-range-of-goods\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":55,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}